Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)

This is a multicenter, prospective, open-label Phase II study designed to evaluate the safety and efficacy of adjuvant sintilimab therapy guided by minimal residual disease (MRD) in patients with Stage II-IIIB non-small cell lung cancer (NSCLC) who have not achieved a pathological complete response (non-pCR) after neoadjuvant immunotherapy combined with chemotherapy. The study is being conducted at the Third People's Hospital of Chengdu and the Guangdong Provincial People's Hospital.

Trial Details

NCT ID
NCT07120698
Phase
PHASE2
Sponsor
Guangdong Association of Clinical Trials
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Sintilimab
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Signed written informed consent prior to the initiation of any trial-related procedures.
  • Male or female aged ≥18 years and ≤75 years.
  • Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
  • Received 3-4 cycles of neoadjuvant immunotherapy (PD-1 inhibitor) combined with chemotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →